Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Chemotherapy in T3N1M0 Nasopharyngeal Carcinoma
NCT05622474Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine and docetaxel in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Failure Free Survival at 2 years. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
gemcitabinedocetaxel
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05622474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05622474.